Welcome to our dedicated page for BIODESIX news (Ticker: BDSX), a resource for investors and traders seeking the latest updates and insights on BIODESIX stock.
Biodesix Inc (BDSX) generates news across diagnostic testing developments, biopharmaceutical partnerships, and clinical validation studies in the lung disease diagnostics sector. As a precision medicine company operating a dual-platform business model, Biodesix's news coverage reflects both its commercial diagnostic testing activities and its research collaborations with pharmaceutical companies.
Diagnostic testing news for Biodesix typically includes updates on test adoption rates, new clinical evidence supporting the utility of its blood-based lung diagnostics, and expansions in insurance coverage or reimbursement policies. The company's Nodify and IQLung testing platforms serve healthcare providers making critical decisions about lung nodule management and cancer treatment, so clinical validation studies and real-world evidence publications represent material developments. Coverage also extends to regulatory milestones such as laboratory certifications and quality accreditations that enable the company to offer diagnostic services.
Biopharmaceutical development services news focuses on contract announcements with pharmaceutical companies, companion diagnostic collaborations, and clinical trial partnerships. These relationships can significantly impact the Development Services segment's revenue trajectory and demonstrate the company's scientific capabilities in biomarker discovery and diagnostic development. News about successful companion diagnostic approvals or clinical trial results using Biodesix's services validates the company's expertise in precision medicine applications.
Financial reporting represents a key news category, with quarterly earnings releases providing insights into test volume trends, revenue performance across the dual business segments, gross margin evolution, and progress toward profitability targets. Investor presentations and strategic updates outline management's vision for expanding market penetration in pulmonology and primary care settings. Technology and scientific news covers advancements in AI-based diagnostic algorithms, multi-omics analysis capabilities, and new biomarker discoveries that could inform future product development.
Biodesix (Nasdaq: BDSX) announced new findings from the Nodify XL2® proteomic test at the CHEST 2022 Annual Meeting, showcasing its effectiveness in evaluating the malignancy risk of pulmonary nodules. Data from the ORACLE study indicates the test performs equally well for nodules identified through lung cancer screenings and incidental findings. With the expansion of eligibility for lung cancer screening in the U.S., the test could help reduce unnecessary biopsies for benign nodules. The presentations highlight the role of blood-based testing in more accurate risk stratification.
Biodesix (BDSX) reported strong preliminary results for Q3 2022, with estimated total revenues between
Biodesix (NASDAQ: BDSX), a leader in data-driven diagnostic solutions for lung disease, announced CEO Scott Hutton will participate in two investor conferences. The Morgan Stanley 20th Annual Global Healthcare Conference is on September 13, 2022, featuring a fireside chat at 9:10 a.m. ET. The H.C. Wainwright 24th Annual Global Investment Conference runs from September 12-14, 2022. Biodesix specializes in non-invasive tests for lung diseases, leveraging advanced AI technology to provide rapid and accurate diagnostic solutions.
Biodesix reported Q2 2022 financial results showing a 52% increase in core lung diagnostic revenue, totaling $7.3 million, compared to the same period in 2021. The overall revenue was $11.0 million, an 8% decline due to decreased COVID-19 testing. The company has received Medicare coverage for its Nodify CDT® test, enhancing long-term margins. Operating expenses rose 21% to $18.6 million, with a net loss of $15.8 million. Biodesix reaffirms its 2022 revenue outlook of $37.5 million to $39.5 million.
Biodesix, a prominent diagnostic solutions company specializing in lung diseases, announced that CEO Scott Hutton will present at the Canaccord Genuity 42nd Annual Growth Conference, scheduled for August 10, 2022, at 3:00 PM ET in Boston. The event will be available for live streaming on Biodesix's website. The company is known for its innovative diagnostic tests, including the Nodify Lung® nodule risk assessment and IQLung™ strategies for lung cancer, aiming to expedite treatment decisions. Biodesix also launched COVID-19 diagnostic tests, responding to the ongoing pandemic.
Biodesix, Inc. (BDSX) has announced promising results from a retrospective analysis of its VeriStrat proteomic test presented by Dr. Young Kwang Chae at the IASLC 2022 World Conference on Lung Cancer in Vienna. This analysis focused on patients with advanced-stage non-small cell lung cancer (NSCLC) treated with Immune Checkpoint Inhibitors (ICIs) and highlighted that the test effectively predicts Progression Free Survival (PFS) and Overall Survival (OS) in patients with low or negative PD-L1 expression.
Biodesix, a diagnostic solutions company focusing on lung disease, will release its Q2 financial results on August 4, 2022, before trading begins. A conference call will take place at 8:00 a.m. ET for a financial discussion and business update. The company's non-invasive tests, such as Nodify Lung and IQLung, aim to improve lung disease diagnostics and treatment decisions. Biodesix utilizes advanced AI for diagnostic solutions and has expanded its testing portfolio in response to the COVID-19 pandemic.
Biodesix, Inc. (Nasdaq: BDSX) announced Medicare coverage for its Nodify CDT® lung nodule test, a significant milestone for lung nodule management. This test is part of Biodesix’s Nodify Lung® Nodule Risk Assessment strategy, which also includes the Nodify XL2® test. Both tests assist physicians in determining whether lung nodules are likely malignant or benign. With all five blood-based diagnostic tests now covered by Medicare, Biodesix aims to enhance patient access and expedite treatment decisions, crucial for lung cancer care.
Biodesix, a leader in diagnostic solutions for lung disease, announced the development of a novel minimal residual disease (MRD) test in collaboration with Memorial Sloan Kettering Cancer Center and Bio-Rad. This initiative, part of a master sponsored research agreement, aims to enhance cancer treatment through advanced diagnostic tests. The project will leverage Biodesix's capabilities in genomics, proteomics, and AI, focusing initially on a highly sensitive MRD test for solid tumors using the ddPCR™ platform. CEO Scott Hutton emphasized this project as a significant milestone.
FAQ
What is the current stock price of BIODESIX (BDSX)?
What is the market cap of BIODESIX (BDSX)?
